About This Site

Fundación de Investigación–Mayagüez was established in 2024 as a sister site to FDI Clinical Research in San Juan, expanding our reach to Puerto Rico’s west coast. As part of the Alcanza Clinical Research Network, the Mayagüez site extends the network’s commitment to operational excellence, data quality, and patient-centered research. 

The Mayagüez team is trained and proficient in FibroScan operation and collaborates with local imaging centers to perform study-required diagnostic procedures. Our experienced team provides a supportive, patient-focused environment where your safety, comfort, and privacy always come first. Led by experienced physicians and supported by a skilled clinical team, we partner with leading pharmaceutical and biotechnology companies to offer clinical trials across a wide range of health conditions—bringing innovative research opportunities closer to the Mayagüez community.

Conditions at this location

Select a condition to learn more about it.

  • Atherosclerotic Cardiovascular Disease (ASCVD)

    Atherosclerotic cardiovascular disease happens when plaque builds up inside the arteries and limits blood flow. This can raise the risk of heart attack, stroke, and other heart-related health problems.

  • Chronic Kidney Disease (CKD)

    Chronic kidney disease happens when the kidneys slowly lose their ability to remove waste and extra fluid from the blood. Early care can help protect kidney function and lower the risk of other health problems.

  • Diabetic Kidney Disease

    Diabetic kidney disease is kidney damage caused by diabetes over time. Finding and managing it early may help slow further damage and protect kidney function.

  • Fatty Liver Disease
  • Nonalcoholic Steatohepatitis (NASH)
  • IgA Nephropathy

    IgA nephropathy is a kidney condition caused by a buildup of a protein called IgA. Over time, it may damage the kidneys and reduce how well they work.

Providers at this location

Ready to be part of healthcare history? Find the right clinical trial for you.